Phase 3 Data: Denifanstat, a First-in-Class, Once-Daily Oral FASN Inhibitor, Hits All Primary Endpoints in Acne Trial
Denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, met all primary, key secondary, and secondary endpoints in a Phase 3 clinical trial for the treatment of moderate-to-severe acne vulgaris, Ascletis Pharma Inc. reports.